The Column Group Information

The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics. TCG’s investment strategy runs counter to the prevailing trend in life sciences venture capital toward assembling diversified portfolios of later stage, single product-orientated companies across multiple industry sectors, with proximity to value inflection points and the early identification of a Pharma “buyer” as key investment considerations. In contrast, TCG takes the long view in making investments, recognizing that significant time is often required to generate significant value. Our approach is not “building-to-exit.” Key variables, including scientific opportunities, the competitive and regulatory landscape, and Pharma priorities, can change very rapidly. Instead, TCG’s mission is the generation of fundamentally strong companies, built from the ground up based on great science and the ability to generate multiple differentiated product opportunities. Rather than diversification, TCG emphasizes focus. We are dedicated to early stage drug discovery as the best source of a new generation of novel, highly effective human therapies. We believe that the most critical resources, such as great ideas, world class founders, and top quality managerial and scientific talent, are very rare and that concentrating them within a small cohort of companies is the key path to success. TCG is about the bold pursuit of big ideas using innovative science to generate breakthrough therapies that address significant diseases. Our firm is committed to all facets of company building and brings together a rich combination of scientific, financial and operational expertise to shape promising science into a value-rich portfolio poised to have a profound impact on human health.